About Contact Us Careers
Sign In

West Syndrome Market Size & Share, by Product Type {Solid Dosage (Tablet, Capsule), Liquid Dosage (Injectable)}; Administration Route (Parenteral, Oral); Treatment (Anticonvulsant, Benzodiazepine, Corticosteroids, Vitamin B); Distribution Channel (Retail, Online, Hospitals); End-user (Hospitals, Homecare, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4397
  • Published Date: Feb 23, 2023
  • Report Format: PDF, PPT

Companies Dominating the West Syndrome Landscape

top-features-companies
    • Marinus Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • SK Biopharmaceuticals Co., Ltd.
    • Alkem Laboratories Ltd.
    • Supernus Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • Abbott Laboratories
    • Upsher-Smith Laboratories, LLC.
    • Pfizer Inc.
    • H. Lundbeck A/S
    • UCB S.A.
Browse Key Market Insights with Data Illustration:

In the News

  • Eisai Co., Ltd. to announce its first presentation with Merck & Co., Inc. associated with the Phase 3 LEAP-002 trial investigating LENVIMA, a receptor tyrosine, orally available and discovered by Eisai. Furthermore, the anti-PD-1 therapy, plus KEYTRUSA, from Merck & Co., Inc., is also introduced as a first-line treatment for uHCC.

  • SK Biopharmaceuticals Co., Ltd. to announce the result of the long-term randomized open-label extension (OLE). The company is focused on treatment development for central nervous system (CNS) disorders. Data analyzed in the OLE phase was taken from nearly 335 adult patients having focal seizures. from nearly 355 adult patients having focal seizures.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4397
  • Published Date: Feb 23, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher prevalence of drug seizures and significant growth in imaging technology are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2033.

Shortage of requisite equipment and skilled medical professionals are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are SK Biopharmaceuticals Co., Ltd., Alkem Laboratories Ltd., Supernus Pharmaceuticals, Inc., Eisai Co., Ltd., Abbott Laboratories, Upsher-Smith Laboratories, LLC., Pfizer Inc., H. Lundbeck A/s and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, administration route, treatment, distribution channel, end-user, and by region.

The solid dosage segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying